Dominic Hollamby has been with Rothschild & Co for nearly 25 years and has advised clients on the buyside and sellside during that time. Julian Hudson is a Partner of Rothschild & Co’s Healthcare team with 20+ years of M&A experience.

Advisors play an important strategic and tactical role in the long and winding road of planning an exit. They are a critical interlocutor between the different buyers and the potential seller of a business or company and using advisors properly can contribute to the ultimate success of a transaction.

Rothschild & Co is one of the leading European healthcare M&A advisors. 

Dominic Hollamby’s notable recent transactions include advising Vectura on the recommended all-cash offer by Philip Morris International in 2021; advising Pfizer on the collaboration agreement with Valneva on its Lyme disease vaccine program in 2020; advising Symphogen on its sale to Servier in 2020; advising SkyCell and its shareholders on their fundraising round led by MVM Partners in 2020, and advising BTG on its sale to Boston Scientific in 2018.

Some of Julian Hudson’s most recent transactions include advising EW Healthcare Partners on the sale of EUSA Pharma to Recordati in 2022; advising Acino Intl. on its sale to Abu Dhabi Development Holding in 2022; advising Ovid on the out-licensing of OV101 European rights to Angelini Pharma in 2020 as well as advising on the sale of Covis Pharma to Apollo and advising EQT ADIA on the acquisition of Nestlé’s Skin Health in 2019.